DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Thrombectomy Under Reopro Versus Alteplase to Treat Stoke

Information source: SOS Attaque Cérébrale
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infarction, Middle Cerebral Artery

Intervention: abciximab IV and thrombectomy (Procedure); alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip) (Drug)

Phase: Phase 4

Status: Terminated

Sponsored by: SOS Attaque Cérébrale

Summary

Intravenous (IV) Alteplase (rt-PA) is the gold standard for brain infarction within 4 h 30 of symptoms onset. Efficacy of this therapy is limited in the setting of large artery occlusions. For middle cerebral artery occlusions (MCA)or internal carotid artery occlusions (ICA), recanalization rates will drop as low as 10%. This element is critical as prognosis is linked to recanalization. Arterial re-occlusions are frequent and may reach 30%, which limits IV thrombolysis efficacy. With the endovascular approach, recanalization rates may reach 90% with last generation devices. A recent meta-analysis has shown that the best candidates for thrombectomy are MCA occlusions. In the coronary literature, endovascular therapy efficacy is increased in association with antiplatelets such as abciximab. The aim of the study was to assess the feasibility of thrombectomy associated with abciximab on revascularisation (TICI score), as well as safety (symptomatic intracranial bleeding), in order to design a clinical trial versus the gold standard for acute ischemic stroke revascularization strategies using IV rt-PA. This is a controlled, pilot study, evaluating feasibility and safety of thrombectomy with abciximab versus IV rt-PA in acute ischemic stroke patients within 4h30 of symptoms onset.

Clinical Details

Official title: Thrombectomy Under Reopro Versus Alteplase and Neurologic Deficit Outcome Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: recanalization rate

Secondary outcome:

Symptomatic intracranial bleeding

percentage of patients with a favorable outcome

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Clinical signs consistent with acute ischemic stroke < 4. 5 hours

- Cerebral infarction and middle cerebral artery occlusion, without any hemorrhage

documented by MRI or CT

- 4 < National Institute of Health Stroke Score (NIHSS) < 25

- age > 18 years

- no prestroke functional dependance : modified Rankin score ≤ 2

- subject or subject's legally authorized representative has signed and dated an

Informed Consent Form according to french regulations and ethic committee. Exclusion Criteria:

- pregnant or lactating female

- coma (vigilance NIHSS > 1)

- epilepsy

- recent history of stroke

- anticoagulant therapy or International Normalized Ratio (INR) > 1. 7 ; heparin therapy

within past 24 hours and Temps de Cephaline Activee (TCA) extension

- previous subarachnoid hemorrhage or clinical presentation suggesting a subarachnoid

hemorrhage, even if initial CT or MRI scan are normal

- known hereditary or acquired hemorrhagics diathesis, coagulation factor deficiency

- uncontrolled hypertension defined as systolic blood pressure ≥ 185 millimeters of

mercury (mmHg) or diastolic blood pressure > 110 mmHg at time of admission and time of threat

- lumbar ar arterial puncture within past 7 days

- major surgery within past 2 months

- gastrointestinal hemorrhage or urinary hemorrhage

- myocardial infarction within past 21 days

- pericarditis within past 3 months

- suspicion of bacterial endocarditis within past 3 months

- previous of aortic dissection

- baseline lab values : TCA > 40, platelets < 100 000/mm3, glucose < 3 mmol/l or > 22

mmol/l

- hepatic insufficiency

- CT or MRI evidence oh hemorrhage

- CT or MRI evidence of mass effect or intra-cranial tumor

- CT showing hypodensity or MRI showing hyperdensity involving greater than 1/3 of the

middle cerebral artery territory (ASPECT score < 7)

Locations and Contacts

Stroke Center, Bichat Hospital, Paris 78018, France
Additional Information

Starting date: September 2013
Last updated: April 24, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017